

Adriana Farias Silva

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2640903/publications.pdf>

Version: 2024-02-01

19
papers

220
citations

933447

10
h-index

1058476

14
g-index

19
all docs

19
docs citations

19
times ranked

216
citing authors

#	ARTICLE	IF	CITATIONS
1	Net charge tuning modulates the antiplasmodial and anticancer properties of peptides derived from scorpion venom. <i>Journal of Peptide Science</i> , 2021, 27, e3296.	1.4	7
2	The wasp venom antimicrobial peptide <sc>polybiaâ€CP</sc> and its synthetic derivatives display antiplasmodial and anticancer properties. <i>Bioengineering and Translational Medicine</i> , 2020, 5, e10167.	7.1	17
3	The effect of lysine substitutions in the biological activities of the scorpion venom peptide VmCT1. <i>European Journal of Pharmaceutical Sciences</i> , 2019, 136, 104952.	4.0	21
4	Peptide Design Enables Reengineering of an Inactive Wasp Venom Peptide into Synthetic Antiplasmodial Agents. <i>ChemistrySelect</i> , 2018, 3, 5859-5863.	1.5	10
5	Angiotensin II-derived constrained peptides with antiplasmodial activity and suppressed vasoconstriction. <i>Scientific Reports</i> , 2017, 7, 14326.	3.3	17
6	Evidences for the action mechanism of angiotensin II and its analogs on <i>Plasmodium</i> sporozoite membranes. <i>Journal of Peptide Science</i> , 2016, 22, 132-142.	1.4	9
7	Antiplasmodial activity of alkyl-substituted 1,2-dioxetanes against <i>Plasmodium falciparum</i> . <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 5007-5008.	2.2	3
8	New linear antiplasmodial peptides related to angiotensin II. <i>Malaria Journal</i> , 2015, 14, 433.	2.3	11
9	Antimalarial Effect of 3â€Methoxyâ€1,2â€Dioxetanes on the Erythrocytic Cycle of <i>Plasmodium falciparum</i>. <i>Chemical Biology and Drug Design</i> , 2015, 86, 1373-1377.	3.2	7
10	Anti-plasmodial activity of bradykinin and analogs. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 3311-3313.	2.2	7
11	Effects of the angiotensin II Ala-scan analogs in erythrocytic cycle of <i>Plasmodium falciparum</i> (in) Tj ETQq1 1 0.784314 rgBT /Qverlock 1.2 6	1.2	6
12	Angiotensin II restricted analogs with biological activity in the erythrocytic cycle of <i>Plasmodium falciparum</i> . <i>Journal of Peptide Science</i> , 2015, 21, 24-28.	1.4	12
13	Highly Potential Antiplasmodial Restricted Peptides. <i>Chemical Biology and Drug Design</i> , 2015, 85, 163-171.	3.2	16
14	The Importance of Ring Size and Position for the Antiplasmodial Activity of Angiotensin II Restricted Analogs. <i>International Journal of Peptide Research and Therapeutics</i> , 2014, 20, 277-287.	1.9	11
15	Antiplasmodial activity study of angiotensin II via Ala scan analogs. <i>Journal of Peptide Science</i> , 2014, 20, 640-648.	1.4	24
16	Effects of Amino Acid Deletion on the Antiplasmodial Activity of Angiotensin II. <i>International Journal of Peptide Research and Therapeutics</i> , 2014, 20, 553-564.	1.9	6
17	A study of the antiâ€plasmodium activity of angiotensin II analogs. <i>Journal of Peptide Science</i> , 2013, 19, 575-580.	1.4	19
18	Copper(II) complexation to 1-octarepeat peptide from a prion protein: Insights from theoretical and experimental UV-visible studies. <i>Journal of Inorganic Biochemistry</i> , 2012, 114, 1-7.	3.5	4

#	ARTICLE	IF	CITATIONS
19	Biological and conformational evaluation of angiotensin II lactam bridge containing analogues. <i>Regulatory Peptides</i> , 2011, 172, 1-7.	1.9	13